Search results for "Crohn's Disease."

showing 10 items of 234 documents

The Role of Laboratory Tests in Crohn's Disease.

2016

In the past, laboratory tests were considered of limited value in Crohn's disease (CD). In the era of biologics, laboratory tests have become essential to evaluate the inflammatory burden of the disease (C-reactive protein, fecal calprotectin) since symptoms-based scores are subjective, to predict the response to pharmacological options and the risk of relapse, to discriminate CD from ulcerative colitis, to select candidates to anti-tumor necrosis factors [screening tests looking for hepatitis B virus and hepatitis C virus status and latent tuberculosis], to assess the risk of adverse events (testing for thiopurine metabolites and thiopurine-methyltransferase activity), and to personalize a…

0301 basic medicineOncologyCrohn’s diseasemedicine.medical_specialtyDiseaseReviewlaboratory testsBioinformaticsInflammatory bowel disease03 medical and health sciences0302 clinical medicineinflammatory bowel diseaseInternal medicinemedicinelcsh:RC799-869Crohn's diseaseLatent tuberculosisThiopurine methyltransferasebiologybusiness.industryGastroenterologymedicine.diseaseUlcerative colitis030104 developmental biologybiology.proteinlcsh:Diseases of the digestive system. Gastroenterology030211 gastroenterology & hepatologyCalprotectinbusinessPharmacogeneticsClinical medicine insights. Gastroenterology
researchProduct

Blood-based prognostic biomarkers in Crohn’s Disease patients on biologics: a promising tool to predict endoscopic outcomes

2021

There is a growing need for biomarkers to predict therapeutic outcome in Crohn's disease (CD).The aim was to evaluate whether NLR (neutrophil-to-lymphocyte ratio), PLR (platelet-to-lymphocyte ratio), ELR (eosinophil-to-lymphocyte ratio), and ENLR (eosinophil*neutrophil-to-lymphocyte ratio), could be prognostic biomarkers of endoscopic response (ER) when starting biologics.Patients with CD who started biologics were enrolled. Multivariate analysis was used to evaluate whether NLR, PLR, ELR and ENLR at baseline and at w12 could predict ER (Simple Endoscopic Score for Crohn's disease [SES-CD] ≤2 or SES-CD≤2 and Rutgeerts i0-i1) after 52 weeks of treatment. Area under the curve (AUC) was calcul…

0301 basic medicineOncologymedicine.medical_specialtyNeutrophilsClinical BiochemistryDisease03 medical and health sciences0302 clinical medicineCrohn DiseaseInternal medicineDrug DiscoverymedicineHumansLymphocytesRetrospective StudiesPharmacologyBiological ProductsCrohn's diseasebusiness.industryfungiOutcome measuresPrognosismedicine.diseaseInflammatory biomarkers030104 developmental biology030220 oncology & carcinogenesisMucosal healingbusinessBiomarkersExpert Opinion on Biological Therapy
researchProduct

Salivary Stress/Immunological Markers in Crohn’s Disease and Ulcerative Colitis

2020

There is continuous and growing interest in research into new alternatives to standard biomarkers to detect and follow-up disease, reducing physical and psychological stress in patients needing regular and invasive medical examinations for the evaluation of pathologies, including inflammatory bowel diseases (IBD). Saliva is one of the most promising body fluids in the research of new biomarkers, thanks to the large number of molecules it contains. Many molecules present in saliva are often directly correlated to their concentration in the blood but may be affected by the condition of the oral cavity. This means that a careful selection of a specific biomarker is required for each pathology,…

0301 basic medicineSalivaReviewDiseaseInflammatory bowel diseaseCatalysislcsh:ChemistryInorganic Chemistrystress03 medical and health sciences0302 clinical medicineImmune systemCrohn Diseaseinflammatory bowel diseasemedicineHumansoxidative stressSalivary Proteins and PeptidesPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologySpectroscopysalivaCrohn's diseasebusiness.industryOrganic Chemistry030206 dentistryGeneral Medicinemedicine.diseaseUlcerative colitisdigestive system diseasescytokinesComputer Science Applicationsimmune system030104 developmental biologylcsh:Biology (General)lcsh:QD1-999ImmunologyBiomarker (medicine)Colitis UlcerativeCalprotectinbusinessBiomarkersInternational Journal of Molecular Sciences
researchProduct

Splenic Littoral Cell Hemangioendothelioma in a Patient With Crohn's Disease Previously Treated With Immunomodulators and Anti-TNF Agents: A Rare Tum…

2011

Th e risk of malignancy in Crohn ’ s disease (CD) has been well described. Moreover, immunomodulators, uch as azathioprine (AZA) and 6-mercaptopurine (6-MP), and biological agents, such as infl iximab and adalimumab, may promote carcinogenesis ( 1 – 3 ). Splenic littoral cell tumors are recently described tumors of vascular origin composed of endothelial cells, with typical microscopic and immunohistochemical features of splenic sinus lining cells ( 4 ). Clinical findings are not specific, and outcome is unpredictable but usually benign, although a few cases with a malignant behavior have been reported ( 5,6 ). We report a 58-year-old Caucasian man with a long history of ileocolonic CD.

6-MercaptopurineMalePathologymedicine.medical_specialtyColonic Diseasemedicine.medical_treatmentAzathioprineSplenic NeoplasmHemangioendotheliomaHemangiomaImmunosuppressive AgentImmunocompromised HostImmunologic FactorCrohn Disease6-Mercaptopurine; Azathioprine; Colonic Diseases; Crohn Disease; Gastrointestinal Agents; Hemangioendothelioma; Hemangioma; Humans; Ileal Diseases; Immunologic Factors; Immunosuppressive Agents; Male; Middle Aged; Splenic Neoplasms; Tumor Necrosis Factor-alpha; Immunocompromised Host; GastroenterologyAzathioprineGastrointestinal AgentMedicineGastrointestinal agentCrohn's diseaseHepatologyTumor Necrosis Factor-alphabusiness.industryGastroenterologyImmunosuppressionMiddle Agedmedicine.diseaseSplenic NeoplasmHemangioendotheliomaImmunologyIleal DiseaseTumor necrosis factor alphaHemangiomabusinessHumanmedicine.drugAmerican Journal of Gastroenterology
researchProduct

Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease.

2008

1. Aliment Pharmacol Ther. 2008 Jun;27(12):1210-23. Epub 2008 Mar 14. Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease. Tinè F, Rossi F, Sferrazza A, Orlando A, Mocciaro F, Scimeca D, Olivo M, Cottone M. Divisione di Gastroenterologia, Azienda Ospedaliera V. Cervello, Palermo, Italy. fabiotinemd@virgilio.it BACKGROUND: Remission and response are the main outcomes to evaluate the efficacy of new treatments for Crohn's disease (CD). AIM: To explain variation of remission and response rates in active luminal CD. METHODS: We studied control patients from trials of biological therapies through articles retriev…

AdultBiological TherapyMalePlacebosTreatment Outcomemetanalysis. biologics.crohn's diseaseCrohn DiseaseDose-Response Relationship DrugRemission InductionHumansFemaleRandomized Controlled Trials as Topic
researchProduct

Metagenomic Analysis of Crohn's Disease Patients Identifies Changes in the Virome and Microbiome Related to Disease Status and Therapy, and Detects P…

2015

Background The aim of this study was to survey the bacterial and viral communities in different types of samples from patients with Crohn's disease (CD) at different stages of the disease to relate their distribution with the origin and progression of this disorder. Methods A total of 42 fecal samples and 15 biopsies from 20 patients with CD and 20 healthy control individuals were collected for bacterial 16S rRNA gene profiling and DNA/RNA virome metagenomic analysis through 454 pyrosequencing. Their composition, abundance, and diversity were analyzed, and comparisons of disease status, patient status, and sample origin were used to determine statistical differences between the groups. Resu…

AdultDNA BacterialMaleAdolescentDiseaseBiologyBioinformaticsBacterial geneticsFecesYoung AdultCrohn DiseaseRNA Ribosomal 16SmedicineImmunology and AllergyHumansHuman viromeMicrobiomeCrohn's diseaseMicrobiotaGastroenterologyCase-control studyMiddle Agedmedicine.diseaseMetagenomicsCase-Control StudiesImmunologyDNA ViralPyrosequencingMetagenomeFemaleMetagenomicsPolymorphism Restriction Fragment LengthInflammatory bowel diseases
researchProduct

Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD)

1995

SUMMARY Hyporesponsiveness to a universe of bacterial and dietary antigens from the gut lumen is a hallmark of the intestinal immune system. Since hyperresponsiveness against these antigens might be associated with inflammation, we studied the immune response to the indigenous intestinal microflora in peripheral blood, inflamed and non-inflamed human intestine. Lamina propria monocuclear cells (LPMC) isolated from inflamed intestine but not peripheral blood mononuclear cells (PBMC) of IBD patients with active inflammatory disease strongly proliferated after co-culture with sonicates of bacteria from autologous intestine (BsA), Proliferation was inhibitable by anti-MHC class II MoAb, suggest…

AdultImmunologyInflammationBiologyPeripheral blood mononuclear cellInflammatory bowel diseaseImmunophenotypingImmune toleranceImmune systemAntigenImmune TolerancemedicineHumansImmunology and AllergyCells CulturedLamina propriaCrohn's diseaseBacteriaMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseIntestinesmedicine.anatomical_structureImmunologyCytokinesmedicine.symptomResearch ArticleClinical and Experimental Immunology
researchProduct

Comparison of US Strain Elastography and Entero-MRI to Typify the Mesenteric and Bowel Wall Changes during Crohn’s Disease: A Pilot Study

2017

Purpose. To evaluate and compare the mesenteric and bowel wall changes during Crohn’s disease (CD) on ultrasonography (US) Strain Elastography (SE) and Enterography Magnetic Resonance Imaging (E-MRI). Methods. From July 2014 to September 2016, 35 patients with ileocolonoscopy diagnosis of CD were prospectively examined with E-MRI and in the same time with US and SE. Results. A total of 41 affected bowel segments and 35 unaffected bowel segments in 35 patients were evaluated. US-SE color-scale coding showed a blue color pattern in the fibrotic mesentery and bowel wall in 15 patients and a green color pattern in the edematous ones in 20 patients. The signal of the bowel wall and mesenteric fa…

AdultMale0301 basic medicineStrain elastographymedicine.medical_specialtyArticle SubjectAdolescentlcsh:MedicinePilot ProjectsMesenteric fatCrohn's disease Ultrasonography Strain ElastographyGeneral Biochemistry Genetics and Molecular BiologyYoung Adult03 medical and health sciences0302 clinical medicineCrohn DiseasemedicineHumansChildMesenteryAgedUltrasonographyAged 80 and overCrohn's diseaseGeneral Immunology and Microbiologymedicine.diagnostic_testbusiness.industrylcsh:RMagnetic resonance imagingGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance ImagingIntestines030104 developmental biologymedicine.anatomical_structureElasticity Imaging TechniquesFemaleRadiologyUltrasonographybusiness030217 neurology & neurosurgeryStatistical correlationResearch ArticleBowel wallBioMed Research International
researchProduct

Antibodies to Cathepsin G in Crohn's disease

1992

. Antibodies directed against antigens in human neutrophils have proved to be of great diagnostic value in certain systemic vasculitides. Recent reports have focused the attention on these antigens as targets of antibodies in sera of patients with inflammatory bowel disease. We investigated the sera drawn from 60 patients suffering from biopsy proven Crohn's disease and 15 patients with active ulcerative colitis. Using sensitive enzyme-linked immunosorbent assays with purified antigens and Western blotting the following antibodies could be demonstrated: cathepsin G (cat-G) antibodies IgG 38.3%, IgM 13.3%, IgA 23.3% and antibodies against human leucocyte elastase (HLE) IgG, IgA, IgM 3.3%. Lo…

AdultMaleCathepsin GAdolescentAnti-nuclear antibodyNeutrophilsBlotting WesternClinical BiochemistryImmunoglobulinsEnzyme-Linked Immunosorbent AssayCathepsin GBiochemistryInflammatory bowel diseasechemistry.chemical_compoundCrohn DiseaseAntigenProteinase 3HumansMedicineChildAgedAutoantibodiesCrohn's diseasePancreatic Elastasebiologybusiness.industrySerine EndopeptidasesGeneral MedicineMiddle Agedmedicine.diseaseCathepsinsUlcerative colitischemistryImmunologybiology.proteinElectrophoresis Polyacrylamide GelFemaleAntibodybusinessEuropean Journal of Clinical Investigation
researchProduct

Hsp60 and Hsp10 increase in colon mucosa of Crohn's disease and ulcerative colitis.

2010

The purpose of this work was to determine in colon mucosa of Crohn’s disease (CD) and ulcerative colitis (UC) in relapse: a) the levels of the chaperonins Hsp60 and Hsp10; b) the quantity of inflammatory cells; and c) if the levels of chaperonins parallel those of inflammation cells. Twenty cases of CD and UC and twenty normal controls (NC) were studied using immunohistochemistry, Western blotting and immunofluorescence. Immunohistochemically, Hsp60 and Hsp10 were increased in both inflammatory bowel diseases (IBD) compared to NC. These results were confirmed by Western blotting. Hsp60 and Hsp10 occurred in the cytoplasm of epithelial cells in CD and UC but not in NC. Hsp60 and Hsp10 co-loc…

AdultMaleColonConnective tissueInflammationBiologyBiochemistryImmune systemSettore MED/38 - Pediatria Generale E SpecialisticaCrohn DiseaseIntestinal mucosaChaperonin 10LeukocytesmedicineHumansIntestinal MucosaColitisIBD HSP 60 HSP 10AgedOriginal PaperLamina propriaCrohn's diseaseEpithelial CellsChaperonin 60Cell BiologyMiddle Agedmedicine.diseaseUlcerative colitismedicine.anatomical_structureImmunologyColitis UlcerativeFemalemedicine.symptom
researchProduct